<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00054106</url>
  </required_header>
  <id_info>
    <org_study_id>I153</org_study_id>
    <secondary_id>CAN-NCIC-IND153</secondary_id>
    <secondary_id>ONCOGENEX-OGX-01-01</secondary_id>
    <secondary_id>CDR0000269888</secondary_id>
    <nct_id>NCT00054106</nct_id>
  </id_info>
  <brief_title>Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer</brief_title>
  <official_title>A Phase I Study Of Combination Neoadjuvant Hormone Therapy And Weekly OGX-011 (Clusterin Antisense Oligonucleotide) Prior To Radical Prostatectomy In Patients With Localized Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as&#xD;
      flutamide and buserelin may stop the adrenal glands from producing androgens. OGX-011 may&#xD;
      help flutamide and buserelin kill more tumor cells by making tumor cells more sensitive to&#xD;
      the drugs. Giving flutamide and buserelin with OGX-011 before surgery may shrink the tumor so&#xD;
      it can be removed during surgery.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining hormone therapy with OGX-011&#xD;
      before radical prostatectomy in treating patients who have prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose and recommended phase II dose of OGX-011 (clusterin&#xD;
           antisense oligonucleotide) when administered with neoadjuvant hormonal therapy before&#xD;
           radical prostatectomy in patients with adenocarcinoma of the prostate.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of OGX-011 when this regimen is administered in these&#xD;
           patients..&#xD;
&#xD;
        -  Assess the effects of this regimen on pathologic complete response rates in these&#xD;
           patients.&#xD;
&#xD;
        -  Correlate plasma and/or prostate concentrations of OGX-011 with patient response or&#xD;
           toxicity measures.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of OGX-011.&#xD;
&#xD;
      Patients receive OGX-011 IV over 2 hours on days 1, 3, 5, 8, 15, 22, and 29; oral flutamide&#xD;
      three times daily for 4 weeks; and buserelin subcutaneously on day 1.&#xD;
&#xD;
      Cohorts of 3-6 patients (except for 1 patient at starting dose) receive escalating doses of&#xD;
      OGX-011 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose&#xD;
      at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. The&#xD;
      recommended phase II dose is the dose preceding the MTD.&#xD;
&#xD;
      Patients undergo radical prostatectomy and bilateral pelvic lymphadenectomy 1 week after the&#xD;
      last dose of neoadjuvant therapy.&#xD;
&#xD;
      Patients are followed at 7 days after surgery and then at 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 25-33 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 6, 2002</start_date>
  <completion_date type="Actual">September 22, 2008</completion_date>
  <primary_completion_date type="Actual">September 23, 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">25</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>buserelin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>custirsen sodium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>flutamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
               -  High-risk, localized disease that is previously untreated&#xD;
&#xD;
               -  Minimum of 2 positive biopsies&#xD;
&#xD;
               -  Meets at least 1 of the following criteria:&#xD;
&#xD;
                    -  Stage T3&#xD;
&#xD;
                    -  Serum PSA greater than 10 ng/mL&#xD;
&#xD;
                    -  Gleason score 7-10&#xD;
&#xD;
                    -  Gleason score 6 and at least 3 positive biopsies&#xD;
&#xD;
          -  Potential candidate for radical prostatectomy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10.0 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST and ALT normal&#xD;
&#xD;
          -  PTT normal&#xD;
&#xD;
          -  INR normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No significant cardiac dysfunction&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No known hypersensitivity to oligonucleotides, luteinizing hormone-releasing hormone&#xD;
             analogs, or anti-androgens&#xD;
&#xD;
          -  No evidence of active uncontrolled infection&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated nonmelanoma skin&#xD;
             cancer&#xD;
&#xD;
          -  No other serious illness, psychiatric disorder, or medical condition that would&#xD;
             preclude study compliance&#xD;
&#xD;
          -  No history of a significant neurological disorder that would preclude informed consent&#xD;
&#xD;
          -  No geographical condition that would preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy for prostate cancer&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No prior hormonal therapy for prostate cancer&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy for prostate cancer&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent heparin or warfarin anticoagulation&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
&#xD;
          -  No other concurrent cytotoxic therapy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim N. Chi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>British Columbia Cancer Agency</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, Tu D, Gleave ME. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst. 2005 Sep 7;97(17):1287-96.</citation>
    <PMID>16145049</PMID>
  </results_reference>
  <results_reference>
    <citation>Chi KN, Eisenhauer E, Fazli L, et al.: A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of OGX-011, a 2'methoxyethyl phosphorothioate antisense to clusterin, in patients with prostate cancer prior to radical prostatectomy. [Abstract] J Clin Oncol 22 (Suppl 14): A-3033, 203s, 2004.</citation>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 5, 2003</study_first_submitted>
  <study_first_submitted_qc>February 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2003</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage II prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flutamide</mesh_term>
    <mesh_term>Buserelin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

